<DOC>
	<DOCNO>NCT02878837</DOCNO>
	<brief_summary>This randomize , open clinical trial seek compare use Midazolam Dexmedetomidine surgery patient regional anesthesia . The primary objective determine superiority either drug intraoperative period regard : 1- Depth sedation 2- incidence complication . Secondary objective include determination superiority regard postoperative period . For , patient randomize two group sedate either Midazolam Dexmedetomidine .</brief_summary>
	<brief_title>Dexmedetomidine v Midazolam Intraoperative Sedation</brief_title>
	<detailed_description>This study randomize , open clinical trial . Patients undergo surgery regional ( neuraxial brachial plexus block ) anesthesia randomly assign one two group . Patients one group ( call MDZ ) initially sedate 0.05mg/Kg bolus dose Midazolam . The one group ( call DEX ) initially sedate load dose 1 µg/Kg Dexmedetomidine 10 minute , follow continuous infusion 0.2 0.8 µg/Kg/h . In order achieve Richmond Agitation-Sedation Scale ( RASS ) score -3 -1 , follow breakthrough dos use necessary : MDZ : 0.02 mg/Kg bolus dose Midazolam plus 0.5µg/Kg bolus dose Fentanyl DEX : 0.5µg/Kg bolus dose Fentanyl Depth sedation incidence complication record surgery , Post Anesthesia Care Unit ( PACU ) Ward two day follow surgery ,</detailed_description>
	<mesh_term>Persistent Vegetative State</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Undergoing surgery regional anesthesia The presence Bradyarrhythmia ; New York Heart Association ( NYHA ) Functional Classes III IV Heart Failure and/or Left Ventricle Ejection Fraction 30 % ; Respiratory Failure , Glasgow Coma Scale score 8 , Liver Failure due increase risk sedation patient condition ( ) refusal participate study withdrawal consent moment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>